Recap: G1 Therapeutics Q4 Earnings
Recap: G1 Therapeutics Q4 Earnings
Shares of G1 Therapeutics (NASDAQ:GTHX) rose in after-market trading after the company reported Q4 results.
的股份G1治療公司(納斯達克:GTHX)在盤後交易中上漲,此前該公司公佈了第四季度業績。
Quarterly Results
季度業績
Earnings per share rose 28.72% year over year to ($0.67), which beat the estimate of ($0.87).
每股盈利較上年同期增長28.72%至0.67美元,超過預估的0.87美元。
Revenue of $16,546,000 up by 0.00% from the same period last year, which beat the estimate of $4,060,000.
營收為16,546,000美元,比去年同期增長0.00%,超過了預期的4,060,000美元。
Looking Ahead
展望未來
G1 Therapeutics hasn't issued any earnings guidance for the time being.
G1治療公司暫時沒有發佈任何盈利指引。
Revenue guidance hasn't been issued by the company for now.
該公司目前尚未發佈營收指引。
How To Listen To The Conference Call
如何收聽電話會議
Date: Feb 24, 2021
日期:2021年2月24日
Time: 04:30 PM
時間:下午4時30分
ET Webcast URL: https://edge.media-server.com/mmc/p/n2his4rc
Price Action
價格行動
Company's 52-week high was at $37.07
該公司52周高點為37.07美元
Company's 52-week low was at $8.80
該公司52周低點為8.80美元
Price action over last quarter: Up 116.89%
上個季度的價格走勢:上漲116.89%
Company Profile
公司簡介
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer such as cell lung cancer and breast cancer and designs them to combine - and enhance - the anti-tumor activity of current therapies.
G1治療公司是一家臨牀階段的生物製藥公司。它致力於開發新的小分子療法,以針對癌症治療中未得到滿足的需求。該公司正在開發有潛力治療大多數類型癌症的藥物,如細胞肺癌和乳腺癌,並設計這些藥物來結合-並增強-當前療法的抗腫瘤活性。
譯文內容由第三人軟體翻譯。